X
SUPN icon

Xponance’s Supernus Pharmaceuticals SUPN Stock Holding History

Xponance’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Buy
5,682
+421
+8% +$20.2K ﹤0.01% 1481
2026
Q1 		$272K Sell
5,261
-605
-10% -$30.8K ﹤0.01% 1328
2025
Q4 		$292K Sell
5,866
-4
-0.1% -$194 ﹤0.01% 1198
2025
Q3 		$281K Buy
+5,870
New +$236K ﹤0.01% 1195

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Xponance's SUPN Position: Q2 2026 in Review

Xponance increased its Supernus Pharmaceuticals (SUPN) stake by 8% in Q2 2026, buying an estimated $20.2K and bringing the position to 5,682 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #1481.

Xponance first reported a position in SUPN in Q3 2025 and has held it in 4 quarters since. The position peaked at $292K in Q4 2025. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Xponance held 5,682 shares of Supernus Pharmaceuticals worth $264K as of Q2 2026.
  • Xponance bought 421 Supernus Pharmaceuticals shares in Q2 2026, an estimated $20.2K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1481 holding.
  • Xponance first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Xponance's Supernus Pharmaceuticals position peaked at $292K in Q4 2025.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.